ARTICLE

Imaging for staging and management of thyroid cancer

Ann D. King

Department of Diagnostic Radiology and Organ Imaging, Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR, China

Corresponding address: Dr A.D. King, Department of Diagnostic Radiology and Organ Imaging, Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR, China.

Email: king2015@cuhk.edu.hk

Date accepted for publication 21 January 2008

Abstract

The management of thyroid cancer has been controversial and, as a result, the routine use of imaging in this disease, especially for pre-operative staging, has lagged behind other head and neck cancers. However, as more is known about the natural history of thyroid cancer, the role of imaging is becoming more established. This review focuses on how imaging now influences the staging and management of the primary cancer, nodal metastases and distant metastases. This is followed by a brief review of the role of imaging in planning post-operative radiotherapy and post-treatment surveillance.

Keywords: Thyroid cancer; imaging; MRI; ultrasound; CT; PET; staging.

Introduction

Thyroid cancer has been increasing, partly as a result of the improved detection of subclinical cancer by imaging, and the incidence is now around 9 per 100,000[1,2]. The four most common primary thyroid cancers, papillary (PC), follicular (FC), medullary (MC), and anaplastic (AC) carcinoma are discussed in this article with the emphasis on PC which accounts for up to 80% of primary thyroid cancers (for the background of each of these cancers, see Table 1). Papillary carcinoma is usually an indolent cancer but it can take an aggressive course in a small number of patients. As a result of this unpredictable behaviour, there has been controversy in the management of thyroid cancer and several different staging systems have developed. Currently the 6th edition of the American Joint Committee on Cancer (AJCC)/International Union Against Cancer (UICC) is the most widely accepted. This classification is based on the TNM staging system and takes into account patient age (cut off 45 years) for PC/FC (Table 2). Irrespective of patient age, MC follows the PC/FC classification for patients 45 years and older, while all patients with AC are considered to have T4 primary tumours and hence advanced stage disease.

| Carcinoma | Frequency (%) | Features |
|-----------|--------------|---------|
| Papillary (PC) | 80 | Generally an indolent tumour with survival >90% at 10 years but a small number are aggressive. Propensity to spread to nodes. Often grouped together with PC in studies of differentiated thyroid cancer. |
| Follicular (FC) | 12–20 | Propensity for haematogeneous spread. Hurtle cell carcinoma is a variant of FC which has a more aggressive course. |
| Medullary (MC) | 5 | Higher mortality than the other differentiated cancers with a propensity for both lymphatic and haematogeneous spread. Familial or associated with the multiple endocrine neoplasia (MEN) syndromes in 25% of patients. Pre-operative biochemical screening for parathyroid and adrenal tumours (phaeochromocytomas are removed before thyroidectomy). Genetic screening is extended to family members in the inherited form. |
| Anaplastic (AC) | 2 | Highly aggressive undifferentiated carcinoma with extrathyroidal extension, nodal and distant metastases. Mean survival only 4–12 months. Often arises in the elderly with multinodular goitre and is thought to develop from pre-existing PC/FC. |
Primary thyroid cancer

Imaging primary thyroid cancer

Ultrasound and ultrasound-guided fine needle aspiration cytology (FNAC) or core biopsy is the investigation of choice for diagnosing primary thyroid cancers. However, thyroid cancers can have a variable appearance on ultrasound and differentiation from benign nodules may sometimes be difficult, some nodules remaining indeterminate on both ultrasound and ultrasound-guided biopsy. A full description of the ultrasound features of thyroid nodules is beyond the scope of this article (for a full description of the ultrasound appearance of benign and malignant thyroid nodules readers are directed to the review of thyroid nodules by Wong et al.\(^3\)), but in general benign nodules are frequently solid hyperechoic/isoechoic nodules or cystic, and may show ultrasound features such as comet tail artefact and rim calcification, while malignant nodules are frequently solid hypoechoic nodules with micro-calciﬁcation and blurred margins and a vascular pattern in which intranodular flow is more dominant than perinodular flow with a high resistive index\(^4,5\). The most common thyroid cancer, PC, usually produces a solid hypoechoic nodule with a well or poorly defined margin, and up to 80% display small foci of punctate calcification\(^6\) (Fig. 1a). This punctate calcification is responsible for much of the success of ultrasound in detecting small thyroid cancers\(^7\), even in those patients with impalpable nodules or co-existing multinodular goitre. Papillary carcinoma may occasionally form cysts which can be the dominant feature (Fig. 1b)\(^8\). The other primary thyroid carcinomas most commonly present as solid hypoechoic nodules or masses (Fig. 2). Medullary carcinoma sometimes shows punctate calcification, calcification is rare in FC, and anaplastic carcinomas are usually large (average size 6 cm) necrotic tumours at diagnosis that extend outside the thyroid gland\(^9\).

Computed tomography (CT) and magnetic resonance imaging (MRI) are inferior to ultrasound for characterizing thyroid nodules, and small carcinomas that are readily identiﬁed by ultrasound, may be undetectable\(^10,11\). The main role of CT and MRI is to demonstrate extrathyroidal tumour extension (see staging below). When PC is demonstrated by computed tomography, punctate calcification or cystic components may be found\(^11\) while on MRI the cystic components can have a high T1 signal intensity.

Table 2 Sixth edition of the AJCC/UICC staging (papillary and follicular carcinoma)

| Stage | T | N  | M   |
|-------|---|----|-----|
| Under 45 years | Any T | Any N | M0 |
| Stage I | T1 | N0 | M0 |
| Stage II | T2 | N0 | M0 |
| Stage III | T3 | N0 | M0 |
| Stage IV | T4a | N0 | M0 |
| Stage IVA | T4a | N1a | M0 |
| Stage IVB | T4a | N1a | M0 |
| Stage IVC | Any T | Any N | M0 |

(a) (b)

Figure 1 Ultrasound of a papillary carcinoma (a) small hypoechoic solid nodule with punctate calcification (arrows), (b) predominantly cystic nodule (arrow heads) with smaller solid component with punctate calcification (arrows).
All four thyroid cancers have been shown to take up $[^{18}\text{F}]\text{fluorodeoxyglucose}$ (FDG), especially the less differentiated tumours. At present, the role of $[^{18}\text{F}]\text{FDG}$ positron emission tomography (PET) in primary thyroid cancer is unclear, but it appears to have a high negative predictive value, and so a role has been proposed to use a negative $[^{18}\text{F}]\text{FDG}$ PET in the inconclusive thyroid nodules to reduce the number of unnecessary thyroid resections for benign nodules$^{[12,13]}$. On the other hand, while $[^{18}\text{F}]\text{FDG}$ PET is a sensitive technique, it has a low specificity caused by uptake in non-malignant conditions such as benign thyroid nodules and thyroiditis. In daily clinical practice this causes problems because 1% of patients undergoing whole body staging for other cancers have ‘incidental’ uptake in the thyroid on $[^{18}\text{F}]\text{FDG}$ PET$^{[14,15]}$. About one-third of these patients turn out to have a malignant nodule, usually a primary thyroid cancer (Fig. 3a,b)$^{[15]}$. Thyroid cancers tend to have a higher standardized uptake value (SUV) than benign disease but there is overlap, and ultrasound and biopsy are often required to make the diagnosis$^{[12,15]}$.

**Figure 2** Ultrasound of solid hypoechoic follicular thyroid cancer (arrows).

**Figure 3** Thyroid nodule (arrows) (a) positive on $[^{18}\text{F}]\text{FDG}$ PET staging scan for a patient with a gastro-intestinal stromal tumour (GIST) and lung cancer; (b) ultrasound and FNAC confirmed a primary papillary carcinoma.

**Table 3** Sixth edition of the AJCC/UICC staging for primary tumour (T stage) (papillary, follicular, medullary and anaplastic carcinoma)

| Stage T1–T2 | 
|-------------|-------------------|
| When small thyroid cancers are confined to the gland, ultrasound is sufficient for staging and no further imaging of the primary is required, unless the tumour abuts ‘blind spots’ on ultrasound such as the midline posterior to the trachea. At present, imaging has little impact on the management of T1 and T2 stage cancer, but there are two controversial areas where ultrasound may become more important in the future. The first of these concerns small T1 tumours. Until recently T1 stage disease was defined as a cancer of $\leq 1$ cm in size (the so-called micropapillary carcinoma), but in the current addition of the AJCC/UICC staging system this has been raised to 2 cm (Table 1). This change brings thyroid staging in line with other head and neck cancers, where 2 cm and... |
4 cm are the important thresholds for the size of primary tumours. However, this move has been controversial because there is evidence to show that patients with cancers of ≤1 cm have a better prognosis than those with cancers between 1 cm and 2 cm\cite{16}. As a result, patients with ≤1 cm PC sometimes undergo lobectomy rather than total thyroidectomy\cite{17}. This is especially the case when an unsuspected PC is found in the histology specimen of a patient who has undergone a lobectomy for multinodular goitre. In these patients completion thyroidectomy is often avoided. Ultrasound of the thyroid now provides a further method by which these subclinical ‘micropapillary’ cancers are detected, raising the question of whether these small ultrasound detected cancers should undergo lobectomy rather than total thyroidectomy.

The second area of controversy is multifocal disease which is common in thyroid cancer, being found in PC (30% involving both lobes equally), MC (especially the familial form) and FC (8%). Multifocal disease can produce macroscopic deposits on ultrasound, the largest deposit being designated the primary cancer. Unfortunately many of the deposits are very small and frequently 2–3 mm hypoechoic nodules are identified by ultrasound which are too small to characterise even with ultrasound-guided FNAC (Fig. 4). The majority of patients with thyroid cancer undergo a total thyroidectomy anyway so pre-operative identification of possible multifocal disease on ultrasound will not change management. Where identification of these deposits could affect management is in those patients who are scheduled to undergo, or have already undergone, a lobectomy and are found to have small deposits in the opposite lobe on ultrasound. However, further management even in these cases is unclear because the clinical significance of multifocal disease is unknown.

**Stage T3–T4**

MRI or CT is required to image the full extent of large thyroid cancers or cancers with extrathyroidal extension, especially T4 tumours (Fig. 5). These modalities may also be required when the primary tumour abuts ‘blind spots’ on ultrasound such as the midline posterior to the trachea. MRI is preferred to CT for staging differentiated carcinomas because it avoids the use of iodinated contrast agents which interfere with the subsequent use of iodine-131/123 for whole body scintigraphy (WBS) and treatment of residual disease and distant metastases. Some patients are unable to tolerate an MR examination because of swallowing and breathing difficulties caused by extensive tumours. In these patients, as well as those with undifferentiated cancers who will not receive 131/123I, CT can be performed instead.

One of the main roles of imaging the primary cancer is to alert the surgeon to the presence of extrathyroidal spread into major structures of the neck. Invasion of these structures may require major reconstructive surgery or render the patient inoperable (Table 3). Tumour invasion into the trachea and oesophagus (T4a) are two sites where major reconstructive surgery may be required, but they are also two sites that are difficult to assess by imaging. Using MRI, tumour invasion into the trachea or oesophagus can be identified with 100% specificity when tumour is found in the inner wall/lumen (Fig. 6)\cite{18,19} and when tumour abuts 180° of the trachea\cite{18} or 270° of the oesophagus\cite{19} (Fig. 7). Unfortunately most patients with invasion of these structures do not show these advanced signs and other more sensitive imaging signs, such as a focal area of abnormality in the outer wall, result in false positive results\cite{18–20}. The recurrent laryngeal nerve can be invaded by thyroid cancers leading to paralysis of the vocal cords. In these cases loss of the fatty tissue in the tracheo-oesophageal groove on one or more contiguous MRI sections has a sensitivity of 94%
and specificity of 82% for tumour invasion of the nerve\(^2\). Cancers that are unresectable fall into the T4b category. Cancers surrounding the carotid artery or mediastinal vessels are unlikely to be resectable\(^2\). Unlike major artery invasion, invasion of the internal jugular vein, which is also well shown by ultrasound, does not influence staging or surgical resectability invasion of the prevertebral fascia tends to be diagnosed at the time of surgery rather than by imaging.

**Nodal thyroid metastases**

**Imaging nodal metastases**

Papillary carcinoma has a high propensity to spread to cervical nodes. The reported incidence varies from 30 to 90%, being higher from surgical series with systematic lymph node excision\(^{23}\). Medullary carcinoma (50%) and AC (40%) also have a high propensity to spread to neck nodes, while lymphatic spread is less common with FC (10%)\(^{17}\). Once again ultrasound is the method of choice for imaging nodal metastases. It is the best modality for assessing abnormalities in the internal architecture, it can be combined with ultrasound-guided FNAC, and the nodes and primary tumour can be evaluated in the same examination. Ultrasound features of metastatic nodes from thyroid cancer are similar to those from other head and neck cancers and include a round shape, loss of the nodal hilum, peripheral vascularity, necrosis and extranodal tumour spread, the latter two features being common in nodes from AC. In addition nodes from PC show calcification (50–69%), increased echogenicity (87%) and cysts (20%), the latter may be the dominant feature with some metastatic nodes being entirely cystic\(^{14,25}\) (Fig. 8a,b). Nodes of PC are frequently small and using a minimum diameter of 7 mm for level II and 6 mm for other levels on ultrasound, Rosario et al.\(^{25}\) reported an accuracy of 89%.
Ultrasound-guided biopsy improves diagnostic accuracy but patients with PC frequently have multiple very small nodes of less than 5 mm and unless punctate calcification is identified, it can be difficult to establish a pre-operative diagnosis. Diagnosis is further hampered by the fact that metastatic nodes from PC may show no change on serial imaging over several years.

Although ultrasound is the primary investigation for PC metastatic nodes, both CT and MRI have imaging features that are helpful in diagnosis. Calcification can be seen on CT as small foci of nodal calcification (Fig. 9). Nodes may be cystic and on MRI can exhibit a high signal on T1-weighted MR images as a result of the thyroglobulin content\(^{[10,26]}\) (Fig. 10). Nodal calcification on CT and high T1 signal nodal cysts on MRI are both unusual features of nodes and when found in a patient being investigated for lymphadenopathy should lead to a hunt for an unknown primary thyroid cancer.

An \(^{131/123}\text{I}\) whole body scan is used following surgery to identify residual or recurrent nodal metastases in the neck and mediastinum. It can miss some iodine negative nodes which tend to be those that arise from less differentiated thyroid cancers. Nodal metastases in the neck and superior mediastinum show uptake on \(^{18}\text{F}\)FDG PET/CT which can demonstrate nodes that are iodine negative. However, in common with all imaging modalities, both false positive and negative results are encountered and \(^{18}\text{F}\)FDG PET/CT may not provide additional benefit over ultrasound and contrast enhanced CT\(^{[27]}\).

### Staging nodal metastases and impact of imaging on patient management (Table 4)

The clinical significance and management of cervical nodal metastases from PC is controversial. In the past, treatment has ranged from a modified radical neck dissection to a more conservative approach involving ‘cherry picking’ nodes at surgery and post-operative radioactive iodine for small nodes. However, with mounting evidence that nodal metastases are a significant risk factor for local recurrence and survival\(^{[28-30]}\), selective neck dissection is becoming the standard treatment\(^{[31]}\). As a result imaging plays a more crucial role in planning surgery. A study by Stulak et al.\(^{[32]}\) has shown that ultrasound has a sensitivity of 83% and specificity of 98% for detecting nodal metastases at presentation and alters the operative procedure even in those patients with palpable nodes. In order to understand how imaging influences management, one needs to be aware of the patterns of nodal spread from thyroid cancer (Fig. 11).

#### Central compartment nodes (stage N1a)

The first echelon of nodes to be involved from thyroid cancer are those in the central compartment (level VI) which includes the periglandular, paratracheal, paralaryngeal, and prelaryngeal nodes on the ipsilateral and sometimes the contralateral side. These nodes are difficult to identify by ultrasound, but for PC, a central compartment dissection is usually routinely performed in all patients undergoing a total thyroidectomy. The exception to this is removal of nodes in the paratracheal and

| NX  | Regional lymph nodes cannot be assessed |
|-----|----------------------------------------|
| N0  | No regional lymph node metastasis       |
| N1  | Regional lymph node metastasis          |
| N1a | Metastasis to Level VI (pretracheal, paratracheal and prelaryngeal/Delphian lymph nodes) |
| N1b | Metastasis to unilateral, bilateral, or contralateral cervical or superior mediastinal lymph nodes |

---

Table 4 Sixth edition of the AJCC/UICC for staging regional lymph nodes (N stage) (papillary, follicular, medullary and anaplastic carcinoma)
paraoesophageal regions inferior to the thyroid around the level of the suprasternal notch. These nodes may not be removed in a standard central compartment resection and are believed to be responsible for some of the so-called ‘thyroid bed’ recurrences, which invade the trachea and oesophagus leading to a high mortality rate. These nodes may also provide an anatomical route by which nodes spread into the superior mediastinum[^133]. Paratracheal nodes in the lower neck/cervicothoracic junction can be visualized by tilting the ultrasound probe down behind the sternum and can also be demonstrated by MRI or CT (Fig. 12a,b).

### Lateral compartment nodes (stage N1b)

The lateral compartment is believed to be the second echelon of nodal spread from thyroid cancer, although not infrequently this may be the first site of lymphatic spread. A study by Machens et al[^34] has shown that this group of nodes are involved almost as frequently as the central group of nodes. Nodal metastases in the lateral compartment preferentially involve nodes in the mid and lower internal jugular chain (III and IV) but may spread into the posterior triangle (V) and supraclavicular fossa. This compartment is not dissected routinely and

---

**Figure 11** Patterns of nodal metastases from differentiated thyroid cancer.

**Figure 12** Paratracheal nodes from papillary carcinoma (a) just inferior to the level of the thyroid demonstrated on axial T1-weighted MRI (arrow) and (b) more inferiorly at the suprasternal notch on axial CT post-contrast (arrow).
identification of metastatic nodes in the ipsilateral compartment of the neck by imaging will lead to a lateral compartment dissection involving nodal levels III, IV and V\cite{35}, dissection is not necessary in those patients with no nodes on ultrasound\cite{36}. Less frequently nodes spread up to the upper internal jugular chain (II) which entails a more extensive surgical approach. Submandibular and submental nodal metastases (level 1) are rare at diagnosis unless there are other nodes present\cite{37}. Nodal metastases to the contralateral neck are not uncommon from MC\cite{34} but are believed to be rare with PC. However, with more widespread use of ultrasound for pre-operative staging, the identification of contralateral nodal metastases from PC is likely to prove more frequent than previously recognized.

**Superior mediastinum compartment nodes (stage N1b)**

The true incidence of mediastinal nodes is largely unknown, although it is known that MC spreads more frequently to this region than PC (Fig. 13). These nodes can be resected via the transcervical route which has a low complication rate apart from hypoparathyroidism\cite{33}. Pre-operative indications for scanning the mediastinum with MRI/CT are not well established but those patients known to be at greatest risk of mediastinal nodes include those with primary tumours invading the superior mediastinum, extensive central compartment nodes (possibly including lower paratracheal nodes identified by neck ultrasound), nodes in the lower lateral neck and contralateral neck nodes\cite{33,38} and, in the case of MC, re-operation for cervical nodes and T4 tumours\cite{39}. At present, imaging of this region is usually only performed post-operatively using $^{131/123}$I WBS.

**Distant thyroid metastases**

*Imaging and staging distant metastases (Table 5)*

Follicular carcinoma has a greater propensity for haematogenous spread than PC, the incidence being 21–33% compared to 2–14%\cite{17,40}. Distant metastases from PC/FC have a more favourable prognosis than most other cancers of the body and patients with distant metastases <45 years are classified as only stage II disease. About 7% of patients with differentiated thyroid cancers have distant metastases at presentation, and in some patients the distant metastasis may be the presenting symptom (Fig. 14)\cite{41}. Distant metastases may also arise many years after the initial diagnosis. Despite the long term survival of patients with well-differentiated cancers the distant metastases are still the major cause of mortality. The most common site for distant metastases from FC/PC are the lung (50%), bone (25%), lung and bone (20%), followed by other sites (5%)\cite{41,42}. Distant metastases from MC are present in 25% of patients and may also involve the liver where deposits over the liver surface are notoriously difficult to diagnose by imaging and may require laparoscopy and biopsy. Distant metastases from AC (stage IVc) are even more frequent, being found in 40% of patients\cite{9}. Imaging distant metastases is usually performed post-operatively for the differentiated

**Table 5 Sixth edition of the AJCC/UICC for staging distant metastases (M stage) (papillary, follicular, medullary and anaplastic carcinoma)**

| MX | Distant metastasis cannot be assessed |
|----|--------------------------------------|
| M0 | No distant metastasis                 |
| M1 | Distant metastasis                   |

*Figure 13* Axial contrast-enhanced CT scan showing metastatic nodes from a medullary carcinoma in the superior mediastinum (arrows).

*Figure 14* Patient with a follicular carcinoma who presented with (a) a liver metastasis on CT (arrow) and over the next 10 years went on to develop multiple metastases in the lung and bone.
thyroid cancers and pre-operatively for AC. The following are the imaging modalities employed to identify distant metastases.

$^{131/123}$I whole body scan

$^{131/123}$I WBS can be used to detect residual locoregional disease in the neck and distant metastases from PC/FC and therefore M staging is performed after surgery (Fig. 15). While the indications for administrating $^{131/123}$I may vary among centres, it is commonly administered to a significant proportion of patients apart from those perceived to be at low risk (small localized primary PC or minimally invasive FC). However, such a diagnostic application is limited by the presence of normal residual thyroid remnants, which are usually present after total thyroidectomy, and which show up as uptake in the thyroid bed region on the post-thyroidectomy scan. In fact, it is increasingly popular to administer a high 'ablativa' dose of $^{131}$I (such as 80 mCi), instead of a low diagnostic dose (such as 1–5 mCi), in the post-thyroidectomy patient, to serve the three-fold purpose of ablating thyroid remnants, screening for residual neck nodes and distant metastases, and eradicating any tumour foci which take up radioactive iodine. The high ablative dose has the advantage over a low diagnostic dose of a higher sensitivity of detection of residual tumour. The ablation of normal remnants serves to facilitate the interpretation of the tumour marker thyroglobulin, which could be 'falsely' elevated by the presence of residual normal thyroid tissue. $^{131/123}$I uptake is reduced by intravenous iodinated contrast agents used for CT and these can interfere with the uptake for at least 1–3 months. Not all thyroid cancers are identified by $^{131/123}$I with MC, AC and some less differentiated PC/FC (including some Hurte cell carcinomas) being iodine-negative.

Chest X ray and CT thorax

Pulmonary metastases produce a micronodular millary pattern or macronodular pattern with similar frequency (Figs. 16 and 17)\[43,44\]. The chest X ray can be normal in one-third of patients with a positive $^{131}$I WBS\[43\], especially in those patients with diffuse mililiary metastases. CT thorax improves the detection of pulmonary metastases but can be also negative in a small number of patients with a positive $^{131}$I WBS\[45-47\]. On the other hand, CT thorax may detect small pulmonary metastases that are not detectable by $^{131}$I WBS. In addition CT

Figure 16  Chest X-ray showing micronodular pulmonary metastases from a papillary carcinoma.

Figure 17  Lung windows from an axial CT thorax showing macronodular pulmonary metastases from a patient with papillary carcinoma (arrow heads).
provides further evaluation of the mediastinal nodes, thoracic cage bony metastases and liver metastases (when the scan is extended down to cover the entire liver). The main role of CT thorax is to detect distant metastases in the post-operative patient with FC/PC who has a negative $^{131}$I WBS and chest X-ray but persistently raised thyroglobulin levels. CT thorax also has a role in the post-operative assessment of MC with raised calcitonin levels and the pre-operative staging of AC.

$[^{18}F]$FDG PET and PET/CT

$[^{18}F]$FDG PET/CT detects distant metastases from PC/FC, some of which are iodine-negative on $^{131}$I WBS\(^{[48,49]}\). However, it can fail to detect small iodine-positive distant metastases such as miliary lung metastases\(^{[50]}\) and it can produce false positive results in the chest from inflammation. The benefits of identifying iodine-negative deposits are limited to the small number of patients who have surgically resectable disease but this situation is likely to change in the future with the introduction of new therapeutic options. For now though, the indications for $[^{18}F]$FDG PET in PC/FC are limited to identifying distant metastases in the post-operative patient with raised thyroglobulin and a negative $^{131}$I WBS. $[^{18}F]$FDG PET has also been shown to identify distant metastases from MC and AC and so may have an even greater potential role in these patients with iodine-negative tumours.

Other imaging modalities

Other modalities such as bone radiographs, scintigraphy and MRI, liver ultrasound/CT, and brain CT can be positive when the $^{131}$I WBS and $[^{18}F]$FDG PET are negative\(^{[51]}\), but these modalities tend to be performed only when there are specific clinical indications. Laparoscopy and laparoscopic biopsy may be required for diagnosis of liver metastases from MC\(^{[52]}\). Scintigraphy is being used in some centres for post-operative assessment of MC using $[^{111}$In]$\text{diethylenetriaminepentaacetic acid (DTPA)}(\text{octreotide,} [^{99m}$Tc(V)]$\text{dimercaptosuccinic acid (DMSA), and} [^{131}$I]$\text{meta-iodobenzylguanidine (MIBG) which offer the prospect of targeted therapy in tumour positive cases}^{[53]}$ (Fig. 18). Radionuclide imaging using thallium-201 and technetium-99m labelled sestamibi are also used in some centres for thyroid cancer but discussion of these techniques is beyond the scope of this article.

**Imaging for post-operative, pre-radiotherapy planning**

Radiotherapy in the form of radioactive iodine (RAI) or external beam radiotherapy is used post-operatively to treat patients with microscopic or macroscopic residual disease. At present the indications for post-operative radiotherapy for thyroid cancer include positive microscopic resection margins, gross unresectable disease at the primary site, and the presence of extensive nodal metastases. Intensity modulated radiotherapy (IMRT) is being increasingly employed for the post-surgical treatment of thyroid cancer, in consideration of the improved distribution of radiation dose compared to conventional radiotherapy. IMRT delivers a high radiation dose to the tumour while shielding vital structures such as the spinal cord. The planning of radiotherapy is based on CT images acquired with the patient in the treatment position. With the use of IMRT, it is possible to assign different radiation dose levels to different regions perceived to be at different levels of risks. A higher dose is given to gross (i.e. imaging visible) tumour compared to a lower dose for sites at increased risk of occult nodal metastases and the site of a positive resection margin. For the purpose of focussing at the site of positive resection margin at the thyroid bed, a pre-operative CT scan or MRI is more helpful than ultrasound, as it is difficult to infer the site of extra-thyroidal extension seen on ultrasound in relation to the CT scan on which radiotherapy planning is executed. A post-operative ultrasound may be valuable to identify any residual nodal disease for radiotherapy planning purposes. In addition residual neck nodes greater than 1 cm detected by imaging may not respond to IMRT (this also applies to the administration of...
radioactive iodine $^{171}$ and should be resected before further treatment (Fig. 19).

**Imaging for post-treatment surveillance and recurrent cancer**

After the first post-operative radioactive iodine scan performed with an ablative dose of radioactive iodine, further $^{131}$I scanning is not necessary if the thyroglobulin level is undetectable under thyroid stimulating hormone stimulation and the post-operative ultrasound is normal. Ultrasound of the neck has been shown to identify recurrent local tumours and neck node metastases in patients with a normal Tg level and normal $^{131}$I WBS $^{34,35}$. Therefore yearly ultrasound of the neck +/- FNA is advocated for surveillance of disease-free patients with PC/FC and normal thyroglobulin (Tg) and antithyroglobulin (TgAb), as well as for patients with MC and normal calcitonin levels. Patients with suspected recurrent cancer (rising biochemistry, ultrasound or clinical suspicion of recurrent tumour) need to undergo re-staging. The neck is imaged initially for local and nodal recurrence using ultrasound but this may need to be followed by MRI or CT. One difficulty for imaging is that metastatic nodes from PC can remain unchanged in size for many years. In addition, metastatic nodes treated with $^{131}$I may not resolve and can remain unchanged over many years. The $^{131/125}$I WBS is used for detection of distant metastases as well as assessing locoregional relapse for PC/FC. Limitations of $^{131/125}$I WBS for MC, AC and some less differentiated PC/FC may result in a greater role for CT thorax/liver and $^{18}$F-FDG PET. Other investigations depend on clinical indications and include bone radiographs, scintigraphy and MRI (spine, femur and pelvis), liver ultrasound/CT, brain CT and for MC, laparoscopy for liver metastases, $^{111}$InDTPA-octreotide, $^{99m}$Tc(V)DMSA and $^{131}$I]MIBG scans.

**Conclusions**

Papillary carcinoma is by far the most frequently encountered thyroid cancer and the unpredictable behaviour of this cancer has led to controversies in the past regarding staging and management. However, as our understanding of this and other thyroid cancers improves, and as new treatments become available, it is clear that imaging will play a vital and ever-increasing role in the management of thyroid cancer.

**Acknowledgements**

I wish to thank Dr Frankie Choi, Dr Cheuk Lun Sham and Dr Sing Fai Leung for their advice on the nuclear medicine, surgical and radiotherapy aspects, respectively, of this article.

**References**

1. Davis L. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 2006; 295: 2164–2167.
2. Colonna M, Guizard AV, Schwartz C et al. A time trend analysis of papillary and follicular cancers as a function of tumour size: a study of data from six cancer registries in France (1983–2000). Eur J Cancer 2007; 43: 891–900.
3. KT Wong, AT Ahuja. Ultrasound of thyroid cancer. Cancer Imaging 2005; 5: 157–66.
4. Chammas MC, Gerhard R, de Oliveira IR et al. Thyroid nodules: evaluation with power Doppler and duplex Doppler ultrasound. Otolaryngol Head Neck Surg 2005; 132: 874–82.
5. Cappelli C, Castellano M, Pirolo I et al. The predictive value of ultrasound findings in the management of thyroid nodules. JOM 2007; 100: 29–35.
6. Appetecchia M, Solivetti FM. The association of colour flow Doppler sonography and conventional ultrasonography improves the diagnosis of thyroid carcinoma. Hormone Res 2006; 66: 249–56.
7. Iannuccilli JD, Cronan JJ, Monchik JM. Risk for malignancy of thyroid nodules as assessed by sonographic criteria: the need for biopsy. J Ultrasound Med 2004; 23: 1455–64.
8. Yuan WH, Chiuo HJ, Chou YH et al. Gray-scale and color Doppler ultrasonographic manifestations of papillary thyroid carcinoma: analysis of 51 cases. Clinical Imaging 2006; 30: 394–401.
9. Kebebew E, Greenspan FS, Clark OH, Woeber KA, McMillan A. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 2005; 103: 1330–5.
10. King AD, Ahuja AT, To EWH, Tse GMK, Metreweli C. Staging of papillary carcinoma of the thyroid: MR imaging vs ultrasound of the neck. Clin Radiol 2000; 55: 222–6.
11. Shetty SK, Maher MM, Hahn PF, Halpern EF, Aquino SL. Significance of incidental thyroid lesions detected on CT: correlation among CT, sonography, and pathology. AJR Am J Roentgenol 2006; 187: 1349–56 (Erratum in AJR Am J Roentgenol 2007; 188: 8).
12. De Geus-Oei LF, Pieters GFFM, Bonenkamp JJ et al. $^{18}$F-FDG PET reduces unnecessary hemithyroidectomies for thyroid nodules with inconclusive cytologic results. J Nucl Med 2006; 47: 770–5.
[13] Mitchell JC, Grant F, Evenson AR, Parker JA, Hasselgren PO. Parangi S. Preoperative evaluation of thyroid nodules with 18F-FDG-PET/CT. Surgery 2005; 138: 1166–75.

[14] Chu QD, Connor MS, Liilen DL, Johnson LW, Turnage RH, Li BD. Positron emission tomography (PET) positive thyroid incidentaloma: the risk of malignancy observed in a tertiary referral center. Am Surg 2006; 72: 272–5.

[15] Bogsrud TV, Karantanis D, Nathan MA et al. The value of quantifying 18F-FDG uptake in thyroid nodules found incidentally on whole-body PET-CT. Nucl Med Commun 2007; 28: 373–81.

[16] Possler C, Scheuba C, Arasi R, Kaczirz K, Kaserer K, Niederle B. Importance of tumour size in papillary and follicular thyroid cancer. Br J Surg 2005; 92: 184–9.

[17] Kebebew E, Clark OH. Differentiated thyroid cancer: ‘complete’ rational approach. World J Surg 2000; 24: 942–51.

[18] Wang JC, Takashima S, Takayama F. Differentiated thyroid cancer: an oncological perspective. Cancer 1985; 55: 794–804.

[19] Wang J, Takashima S, Matsushita T, Takayama F, Kobayashi T, Kadoya M. Esophageal invasion by thyroid carcinomas: prediction using magnetic resonance imaging. J Comput Assist Tomogr 2003; 27: 18–25.

[20] Roychowdhury S, Loewer LA, Yousen DM, Chalian A, Montone KT. MR imaging for predicting neoplastic invasion of the cervical esophagus. AJNR Am J Neuroradiol 2000; 21: 1681–7.

[21] Takashima S, Takayama F, Wang J, Kobayashi S, Kadoya M. Using MR imaging to predict invasion of the recurrent laryngeal nerve by thyroid carcinoma. AJR Am J Roentgenol 2003; 180: 837–42.

[22] Yousen DM, Hatabu H, Hurst RW et al. Carotid artery invasion by head and neck masses: prediction with MR imaging. Radiology 1995; 195: 715–20.

[23] Oguchi S, Oguchi A, Murakami N. Papillary carcinoma of the thyroid I. developing pattern of metastasis. Cancer 1970; 26: 1053–60.

[24] Ahuja AT, Chow L, Chik W, King W, Metreweli C. Metastatic cervical nodes in papillary thyroid carcinoma: comparison with ultrasound and histological correlation. Clin Radiol 1995; 50: 229–31.

[25] Rosario PW, de Faria S, Bicalho L. Ultrasound differentiation between metastatic and benign lymph nodes in patients with papillary thyroid carcinoma. J Ultrasound Med 2005; 24: 1385–9.

[26] Som PM, Brandwein M, Lidov M, Biller HF. The varied presentations of papillary thyroid carcinoma cervical nodal disease: CT and MR findings. Am J Neuroradiol 1994; 15: 1123–8.

[27] Jeong HS, Baek CH, Son YI et al. Integrated 18F-FDG PET/CT for the initial evaluation of cervical node level of patients with papillary thyroid carcinoma: comparison with ultrasound and contrast-enhanced CT. Clin Endocrinol 2006; 65: 402–7.

[28] Tubiana M, Schlumberger M, Rougier P et al. Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer 1985; 55: 794–804.

[29] Moguchi S, Murakami N, Yamashita H, Toda M, Kawamoto H. Papillary thyroid carcinoma: modified radical neck dissection improves prognosis. Arch Surg 1998; 133: 276–80.

[30] Lundgren CI, Hall P, Dickman PW, Zedenius J. Clinically significant prognostic factors for differentiated thyroid carcinoma. Cancer 2006; 106: 524–31.

[31] Palazzo FF, Gnosnelli J, Savio R et al. Lymphadenectomy for papillary thyroid cancer: changes in practice over four decades. Eur J Surg Oncol 2006; 32: 340–4.

[32] Stulak JM, Grant CS, Farley DR et al. Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer. Arch Surg 2006; 141: 489–96.

[33] Khoo MLC, Freeman JL. Transcervical superior mediastinal lymphadenectomy in the management of papillary thyroid carcinoma. Head Neck 2003; 25: 10–14.

[34] Machens A, Hinze R, Thomosch O, Drahle H. Pattern of nodal metastasis for primary and reoperative thyroid cancer. World J Surg 2002; 26: 22–8.

[35] Watkinson JC, Franklyn JA, Olliff JF. Detection and surgical treatment of cervical lymph nodes in differentiated thyroid cancer. Thyroid 2006; 16: 187–94.

[36] Ito Y, Tomoda C, Urano T et al. Preoperative ultrasonographic examination for lymph node metastasis: usefulness when designing lymph node dissection for papillary microcarcinoma of the thyroid. World J Surg 2004; 28: 498–501.

[37] Amarasinghe YI, Perera NMA, Bahinathan N, Marzook HH, Peiris AKC. Review of distribution of nodal disease in differentiated thyroid cancers in an oncological center in Sri Lanka. Ann Surg Oncol 2007; 14: 1560–4.

[38] Sugeno Y, Asanuma K, Shingu R et al. Clinical evaluation of upper mediastinal dissection for differentiated thyroid carcinoma. Surgery 1993; 113: 541–5.

[39] Machens A, Holzhausen HJ, Drahle H. Prediction of mediastinal lymph node metastasis in medullary thyroid carcinoma. Br J Surg 2004; 91: 709–12.

[40] Benbasat CA, Mechlis-Frisch S, Hirsch D. Clinicopathological characteristics and long-term outcome in patients with distant metastases from differentiated thyroid cancer. World J Surg 2006; 30: 1088–95.

[41] Baudin E, Schlumberger M. New therapeutic approaches for metastatic thyroid carcinoma. Lancet Oncol 2007; 8: 148–56.

[42] Haq M, Hamer C. Differentiated thyroid carcinoma with distant metastases at presentation: prognostic factors and outcome. Clin Endocrinol 2005; 63: 87–93.

[43] Ronga G, Filesi M, Montesano T et al. Lung metastases from differentiated thyroid carcinoma. A 40 years’ experience. Q J Nucl Med Mol Imaging 2004; 48: 12–9.

[44] Durante C, Haddy N, Baudin E et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radiiodine therapy. J Clin Endocrinol Metab 2006; 91: 2892–9.

[45] Kaucuk ON, Gultekin SS, Aras G, Isik E. Radiiodine whole-body scans, thyroglobulin levels, 99mTc-MIBI scans and computed tomography: results in patients with lung metastases from differentiated thyroid cancer. Nucl Med Commun 2006; 27: 261–6.

[46] Bai CS, Kumar A, Chandra P, Dwivedi SN, Mukhopadhyaya S. Is chest x-ray or high-resolution computed tomography scan of the chest sufficient investigation to detect pulmonary metastasis in pediatric differentiated thyroid cancer? Thyroid 2004; 14: 217–25.

[47] Ilgan S, Karacalioğlu AO, Pabuscu Y et al. Iodine-131 treatment and high-resolution CT: results in patients with lung metastases from differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 2004; 31: 825–30.

[48] Chung JK, So Y, Lee JS et al. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan. J Nucl Med 1999; 40: 986–92.

[49] Wang W, Macapinlac H, Larson SM et al. 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic 131I whole-body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 1999; 84: 2291–302.

[50] Dietlein M, Scheidhauer K, Voth E, Theissen P, Schicha H. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Med 1997; 24: 1342–8.

[51] Shiga T, Tsukamoto E, Nakada K et al. Comparison of 18F-FDG, 131I-Na, and 201Tl in diagnosis of recurrent or metastatic thyroid carcinoma. J Nucl Med 2001; 42: 414–9.
[52] Nanni C, Rubello D, Fanti S et al. Role of $^{18}$F-FDG-PET and PET/CT imaging in thyroid cancer. Biomed Pharmacother 2006; 60: 409–13.

[53] Gao Z, Biersack HJ, Ezziddin S, Logvinski T, An R. The role of combined imaging in metastatic medullary thyroid carcinoma: $^{111}$In-DTPA octreotide and $^{131}/^{123}$I-MIBG as predictors for radio-nuclide therapy. J Cancer Res Clin Oncol 2004; 130: 649–56.

[54] Antonelli A, Miccoli P, Ferdeghini M et al. Role of neck ultrasonography in the follow-up of patients operated on for thyroid cancer. Thyroid 1995; 5: 25–8.

[55] Frasoldati A, Pesenti M, Gallo M, Caroggio A, Salvo D, Valcavi R. Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma. Cancer 2003; 97: 90–6.